批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2022/11/22 |
SUPPL-47(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2021/07/16 |
SUPPL-45(补充) |
Approval |
Efficacy |
PRIORITY
;Orphan
|
|
|
2020/12/30 |
SUPPL-44(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2019/06/11 |
SUPPL-42(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/12/02 |
SUPPL-41(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/05/24 |
SUPPL-40(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2015/07/01 |
SUPPL-37(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2015/05/19 |
SUPPL-38(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/09/04 |
SUPPL-36(补充) |
Approval |
Labeling |
STANDARD
;Orphan
|
|
|
2013/08/16 |
SUPPL-35(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2012/08/14 |
SUPPL-34(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/07/05 |
SUPPL-33(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/02/06 |
SUPPL-31(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/07/14 |
SUPPL-30(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2011/07/14 |
SUPPL-28(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2009/05/19 |
SUPPL-21(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2009/02/13 |
SUPPL-26(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2006/04/27 |
SUPPL-20(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2006/03/29 |
SUPPL-19(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2005/12/13 |
SUPPL-18(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2004/06/16 |
SUPPL-13(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2001/07/25 |
SUPPL-12(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2000/12/01 |
SUPPL-10(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
1998/04/20 |
SUPPL-7(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1997/04/22 |
SUPPL-6(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
1997/04/22 |
SUPPL-5(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
1996/04/25 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1995/06/22 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1994/04/08 |
ORIG-1(原始申请) |
Approval |
Type 3 - New Dosage Form |
PRIORITY
;Orphan
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
001 |
5260301 |
2011/02/28 |
|
Y |
|
|
|
PDF格式 | **本条是由Drugfuture回溯的历史信息** |
与本品治疗等效的药品
活性成分:TACROLIMUS 剂型/给药途径:INJECTABLE;INJECTION 规格:EQ 5MG BASE/ML 治疗等效代码:AP
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
050709 |
001 |
NDA |
PROGRAF |
TACROLIMUS |
INJECTABLE;INJECTION |
EQ 5MG BASE/ML |
Prescription |
Yes |
Yes |
AP |
1994/04/08
|
ASTELLAS |
203900 |
001 |
ANDA |
TACROLIMUS |
TACROLIMUS |
INJECTABLE;INJECTION |
EQ 5MG BASE/ML |
Discontinued |
No |
No |
AP |
2017/08/25
|
HOSPIRA |